CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance

CVRx, Inc.

• U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.
• Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.
• First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.
• FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.
• Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.